Lazertinib
Phase 2UNKNOWN 3 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer Stage III
Conditions
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
Trial Timeline
Jun 30, 2022 → Mar 2, 2026
NCT ID
NCT05338619About Lazertinib
Lazertinib is a phase 2 stage product being developed by Yuhan for Non-small Cell Lung Cancer Stage III. The current trial status is unknown. This product is registered under clinical trial identifier NCT05338619. Target conditions include Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Non-small Cell Lung Cancer Stage III were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05716672 | Pre-clinical | UNKNOWN |
| NCT05338619 | Phase 2 | UNKNOWN |
| NCT04075396 | Phase 1/2 | Completed |
Competing Products
20 competing products in Non-small Cell Lung Cancer Stage III